Concert Pharmaceuticals Historical PE Ratio image   This CNCE PE ratio history page last updated 3/15/2023
Concert Pharmaceuticals Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/7/2022
4.45-0.58-2.32NA
Q2 2022
8/4/2022
6.15-0.59-2.36NA
Q1 2022
5/5/2022
3.26-1.03-4.12NA
Q4 2021
3/3/2022
2.78-1.01-4.04NA
Q3 2021
11/9/2021
3.84-0.78-3.12NA
Q2 2021
8/5/2021
3.560.160.645.6
Q1 2021
5/4/2021
3.87-0.67-2.68NA
Q4 2020
2/25/2021
6.87-0.69-2.76NA
Q3 2020
11/5/2020
10.90-0.60-2.40NA
Q2 2020
8/6/2020
9.35-0.41-1.64NA
Q1 2020
4/30/2020
9.98-0.70-2.80NA
Q4 2019
2/27/2020
10.18-0.86-3.44NA
Q3 2019
11/7/2019
6.40-0.72-2.88NA
Q2 2019
8/1/2019
10.94-0.78-3.12NA
Q1 2019
5/2/2019
9.96-0.93-3.72NA
Q4 2018
2/28/2019
15.19-0.89-3.56NA
Q3 2018
11/1/2018
14.66-0.74-2.96NA
Q2 2018
8/2/2018
17.52-0.57-2.28NA
Q1 2018
5/3/2018
19.68-0.19-0.76NA
Q4 2017
3/1/2018
21.04-0.26-1.04NA
Q3 2017
11/9/2017
16.465.4421.760.8
Q2 2017
8/8/2017
14.22-0.58-2.32NA
Q1 2017
5/2/2017
15.74-0.60-2.40NA
Q4 2016
3/6/2017
15.64-0.54-2.16NA
Q3 2016
11/8/2016
8.20-0.51-2.04NA
Q2 2016
8/9/2016
11.62-0.60-2.40NA
Q1 2016
5/5/2016
12.01-0.63-2.52NA
Q4 2015
3/1/2016
14.210.030.12118.4
Q3 2015
11/5/2015
20.42-0.39-1.56NA
Q2 2015
8/5/2015
17.25-0.37-1.48NA
Q1 2015
5/8/2015
13.79-0.48-1.92NA
Q4 2014
2/3/2015
12.89-0.56-2.24NA
Q3 2014
11/12/2014
12.83-0.43-1.72NA
Q2 2014
8/12/2014
8.60-0.45-1.80NA
Q1 2014
5/14/2014
9.54-0.76-3.04NA
FY 2013
3/31/2014
13.45-4.99-19.96NA
Concert Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/7/2022
4.45-0.58-3.21NA
Q2 2022
8/4/2022
6.15-0.59-3.41NA
Q1 2022
5/5/2022
3.26-1.03-2.66NA
Q4 2021
3/3/2022
2.78-1.01-2.30NA
Q3 2021
11/9/2021
3.84-0.78-1.98NA
Q2 2021
8/5/2021
3.560.16-1.80NA
Q1 2021
5/4/2021
3.87-0.67-2.37NA
Q4 2020
2/25/2021
6.87-0.69-2.40NA
Q3 2020
11/5/2020
10.90-0.60-2.57NA
Q2 2020
8/6/2020
9.35-0.41-2.69NA
Q1 2020
4/30/2020
9.98-0.70-3.06NA
Q4 2019
2/27/2020
10.18-0.86-3.29NA
Q3 2019
11/7/2019
6.40-0.72-3.32NA
Q2 2019
8/1/2019
10.94-0.78-3.34NA
Q1 2019
5/2/2019
9.96-0.93-3.13NA
Q4 2018
2/28/2019
15.19-0.89-2.39NA
Q3 2018
11/1/2018
14.66-0.74-1.76NA
Q2 2018
8/2/2018
17.52-0.574.424.0
Q1 2018
5/3/2018
19.68-0.194.414.5
Q4 2017
3/1/2018
21.04-0.264.005.3
Q3 2017
11/9/2017
16.465.443.724.4
Q2 2017
8/8/2017
14.22-0.58-2.23NA
Q1 2017
5/2/2017
15.74-0.60-2.25NA
Q4 2016
3/6/2017
15.64-0.54-2.28NA
Q3 2016
11/8/2016
8.20-0.51-1.71NA
Q2 2016
8/9/2016
11.62-0.60-1.59NA
Q1 2016
5/5/2016
12.01-0.63-1.36NA
Q4 2015
3/1/2016
14.210.03-1.21NA
Q3 2015
11/5/2015
20.42-0.39-1.80NA
Q2 2015
8/5/2015
17.25-0.37-1.84NA
Q1 2015
5/8/2015
13.79-0.48-1.92NA
Q4 2014
2/3/2015
12.89-0.56-2.20NA
Q3 2014
11/12/2014
12.83-0.43-6.63NA
Q2 2014
8/12/2014
8.60-0.45NANA
Q1 2014
5/14/2014
9.54-0.76NANA
FY 2013
3/31/2014
13.45-4.99NANA
Quotes delayed 20 minutes

Email EnvelopeFree CNCE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Concert Pharmaceuticals (CNCE) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CNMD PE Ratio History
CNSP PE Ratio History
CNST PE Ratio History
CNTX PE Ratio History
CNVY PE Ratio History
COCP PE Ratio History
CODX PE Ratio History
COGT PE Ratio History
COLL PE Ratio History
COO PE Ratio History
How should the CNCE historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Concert Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this CNCE Historical PE Ratio page.

What is the average historical PE for CNCE based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The CNCE historical PE ratio using the annualized quarterly earnings method works out to 41.6.

What is the average historical PE for CNCE based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The CNCE historical PE ratio using the TTM earnings method works out to 4.6.

On this page we presented the Concert Pharmaceuticals Historical PE Ratio information for Concert Pharmaceuticals' stock. The average CNCE historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 41.6. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CNCE historical PE based on this TTM earnings result method is 4.6. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CNCE historical PE result, against the recent PE: when this page was posted on 3/6/2023, the most recent closing price for CNCE had been 8.37, and the most recent quarterly earnings result, annualized, was 0.64. Meanwhile, the most recent TTM earnings summed to 4.42. From these numbers, we calculate the recent CNCE PE on 3/6/2023 based on annualized quarterly EPS was 13.1. Based on CNCE's history, that recent PE is low relative to the historical average, with the recent PE 68.5% lower than the historical average PE across our data set for Concert Pharmaceuticals. Looking at the recent CNCE PE on 3/6/2023 based on TTM EPS, we calculate the ratio at 1.9. Based on CNCE's history, that recent PE is low relative to the historical average, with the recent PE 58.7% lower than the average PE across our Concert Pharmaceuticals data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on CNCE or any other given stock, valuation analysis for CNCE can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Concert Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CNCE. Thanks for visiting, and the next time you need to research CNCE Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: XLV YTD Return, Qualcomm YTD Return, WPP Options Chain.

 

Concert Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.